RNA polymerase (RNAP) is a well-validated target for the development of antibacterial and antituberculosis agents. Because the purification of large quantities of native RNA polymerase from pathogenic mycobacteria is hazardous and cumbersome, the primary screening was carried out using Escherichia coli RNAP. The authors have developed a high-throughput screening (HTS) assay to screen for novel inhibitors of RNAP. In this assay, a fluorescent analog of UTP, gamma-amino naphthalene sulfonic acid (γ-AmNS) UTP, was used as one of the nucleotide substrates. Incorporation of UMP in RNA results in the release of γ-AmNS-PPi, which has higher intrinsic fluorescence than (γ-AmNS) UTP. The assay was optimized in a 384-well format and used to screen 670,000 compounds at a concentration of 10 µM. About 0.1% of the compounds showed more than 60% inhibition in the primary HTS. All the primary actives tested for dose response using the same assay had an EC 50 below 100 µM. Eighty percent of the primary HTS actives obtained using E. coli RNAP showed comparable activity against Mycobacterium smegmatis RNAP in the conventional radioactive assay. Activity of hits selected for the hit-to-lead optimization was also confirmed against Mycobacterium bovis RNAP which has >99% sequence identity with Mycobacterium tuberculosis RNAP subunits. (Journal of Biomolecular Screening 2006:968-976) 
INTRODUCTION
T UBERCULOSIS IS THE LEADING CAUSE OF MORTALITY from a single infectious agent and is responsible for 2 million deaths per year. Someone in the world is infected with tuberculosis (TB) every second. Overall, one-third of the world's population has been exposed and thus potentially infected with the TB bacillus, but only 5% to 10% of these show clinical signs of the disease at some time during their lifetime. Current drugs for the treatment of TB were discovered more than 40 years ago, and since then, there has not been any successful development of novel therapeutic agents. Combination therapy for TB includes 4 drugs-rifampicin, isoniazid, pyrizinamide, and ethambutolgiven for a minimum duration of 6 months. Use of multiple drugs helps in preventing the appearance of drug-resistant mutants, and 6 months of treatment helps in preventing relapse.
New drugs with a potential to reduce this duration to less than 4 months will have a major impact on transmission of TB. Drug resistance to the frontline drugs such as isoniazid and rifampicin is as high as 14% in certain regions of the world. Therefore, there is an urgent medical need to discover novel antimycobacterial agents that are rapidly effective against drug-resistant as well as drug-sensitive TB. Rifampicin is one of the most crucial drugs for TB treatment and is the most potent sterilizing agent in the regimen. Rif-resistant TB requires more than an 18-month-long treatment. Rifampicin resistance maps almost exclusively to mutations in the rpoB gene encoding the beta subunit (rifampicin binding site) of RNA polymerase (RNAP), further confirming that RNAP is a valid drug target, and novel inhibitors of RNAP may be developed as highly potent drugs for Rif-resistant TB.
In eukaryotic cells, 3 different RNA polymerases-RNAP I, II, and III-are involved in ribosomal, messenger, and transfer RNA synthesis, respectively. All RNA polymerases are highly conserved in the active site region. Therefore, selectivity of inhibition is essential to avoid mechanism-based toxicity. Because RNA polymerase is a multisubunit enzyme, it gives us an opportunity to find inhibitors that can bind at various sites apart from the active site and thereby specifically inhibit the prokaryotic enzyme.
Core RNA polymerase is a stable, noncovalent assembly of 1β, 1β′, 2α and 1ω subunit. The core enzyme catalyzes the synthesis of the RNA polymer, whereas promoter-specific transcription initiation requires both, the core enzyme and the σ subunit, which together comprise the holoenzyme. The Mycobacterium tuberculosis genome encodes 13 different putative σ factors. 1 It is generally observed that every σ factor recognizes a specific set of promoters, thus allowing different σ factors to initiate transcription of different subsets of genes. The housekeeping sigma factor, σA, identified as the homologue of Escherichia coli σ70, has been shown to be essential for the survival, as well as virulence, of M. tuberculosis. 1 The technical limitations in purifying large quantities of wild-type core RNAP from pathogenic mycobacterial species prompted the use of reconstituted E. coli core/σ70 holoenzyme for the high-throughput screening (HTS) campaign. The activity of the hits was confirmed against Mycobacterium smegmatis and/or Mycobacterium bovis BCG core enzyme with recombinant M. tuberculosis σA. The E. coli and M. tuberculosis core enzyme, as well as the respective housekeeping sigma factors, E. coli σ70 and M. tuberculosis σA, shares an overall sequence identity of 40-50% (Table 1) , which may translate to missing inhibitors specific for the M. tuberculosis enzyme.
We describe here a homogeneous assay suitable for HTS of E. coli RNAP inhibitors and activity of hits against mycobacterial RNAP.
The fluorescent analog of UTP used in this assay contained amino naphthalene sulfonic acid (AmNS) in a phosphoamide linkage with the gamma phosphate group on UTP. The fluorescence of AmNS is quenched when bound to UTP, and upon incorporation of the UMP portion into the growing RNA chain, there is a significant increase in the fluorescence, which is used as the readout.
MATERIALS AND METHODS
1-Ethyl-3-(3-Dimethylaminopropyl) carbodiimide (EDAC), UTP, phenylmethylsulphonylfluoride (PMSF), Tris base, NaCl, polyethyleneimine (PEI), glycerol, NaN 3 , DTT KCl, adenosine triphosphate (ATP), guanosine triphosphate (GTP), and cytidine triphosphate (CTP) were purchased from Sigma (St. Louis, MO). 1-Aminonaphthalene-5-sulfonic acid (AmNS) was obtained from Fluka (Buchs SG, Switzerland). 3 H-CTP (20 Ci/mmol) was obtained from Amersham (Piscataway, NJ). Microplates (96-and 384-well) for the fluorescent assay were purchased from Costar, Inc. (Acton, MA) or from Nunc, Inc. (Pittsburgh, PA). T4 phage DNA was supplied by Bangalore Genei Pvt. Ltd. (Bangalore, India). For the radioactive assay, nuclease-free, UV-sterilized ScreenMate plates from Matrix Technologies (Hudson, NH) were used for the assay, and Multiscreen plates (MAFBNOB) from Millipore, Inc. (Billerica, MA) were used for filtering the trichloroacetic acid (TCA)-precipitated RNA product.
Synthesis and purification of (γ-AmNS)UTP
Synthesis of (γ-AmNS) UTP involved a single-step coupling reaction between UTP and AmNS using a water-soluble carbodiimide. 2, 3 AmNS was recrystallized from water (soluble at 2 g/L) in the form of pale pink needles. AmNS (2.5 mmol or 0.555 g) was dissolved in 10 mL of water, and the pH was adjusted to 5.6 using freshly prepared 1 N NaOH. UTP (0.5 mmol or 0.240 g) was dissolved in 5 mL of water, and the pH was adjusted to 5.6 using 1 N HCl. This UTP solution was treated with 2.5 mmol (0.479 g) of EDC (N-ethyl-N´-(3dimethylaminopropyl) carbodiimide), and the reaction mixture was stirred at room temperature for 16 h. During the reaction, the pH was maintained at 5.6 ± 0.4 by periodic addition of 1 N HCl. Progress of the reaction was monitored using thin-layer chromatography (TLC). After 16 h, the reaction mixture was filtered off to remove any undissolved residues, and the supernatant was diluted to a final volume of 50 mL with 50 mM triethyl ammonium bicarbonate (TEAB) buffer at pH 7.5. Purification of the product was performed on a DEAE-Sepharose column at 4 °C. The pH of the reaction mixture was adjusted to 2.5 using 1 N HCl, and AmNS precipitate was removed by filtration. The pH of the supernatant was adjusted to 7.5 using triethanolamine (TEA) and then loaded onto a DEAE-Sepharose column equilibrated with 50 mM TEA buffer, pH 7.5. The column was washed with 3 column volumes of 50 mM TEA buffer and eluted with 2400 mL gradient of 50 to 1000 mM TEAB at a flow rate of 1 ml/min. Fractions, 45 mL each, were analyzed by measuring absorbance at 260 nm and fluorescence (λex/λem of 360/500 nm). The order of elution was AmNS, UTP, followed by (γ-AmNS) UTP. The absorbance and fluorescence profile of column fractions indicated that (γ-AmNS) UTP eluted between 700 and 900 mM TEA buffer (Fig. 1A) . The fractions containing (γ-AmNS) UTP were pooled and freeze-dried. This material was redissolved in water and freeze-dried again to remove traces of TEA. The purified product was reconstituted in 50 mM Tris-Cl, pH 8.0, and stored at -70 °C. The whole procedure was carried out with minimum exposure to light. Activity of individual batches was checked in the enzyme assay ( Table 2) . Purity of the final product was checked using TLC and high-performance liquid chromatography (HPLC). TLC was performed on silica gel using a solvent system consisting of 6.0 mL isopropyl alcohol, 1.5 mL 25% ammonia, and 2.5 mL water. HPLC was performed on a Kromasil 100 C18 column (0.46 × 25 cm). The sample was loaded in a 50-mM triethanolamine acetate buffer, pH 6.0 (solvent B), and eluted using acetonitrile (solvent A) at a flow rate of 1 mL/min. A 5-step gradient was used during elution: 100% B for 5 min, 100% to 95% B in 10 min, 95% B for 5 min, 95% to 90% B in 20 min, and 95% to 100% B in 5 min. Purity as per TLC (Fig. 1B) , as well as HPLC analysis (data not shown), was found to be more than 95%. Final yield of the purified (γ-AmNS) UTP was in the range of 15% to 20%, and it was stable for several weeks when stored at -20 °C or -70 °C.
Sigma dependence
Purification of core RNAP and sigma factors is described in the appendix. Core RNAP was checked for sigma dependence using σ70 for E. coli and σA of M. tuberculosis for M. smegmatis or M. bovis BCG RNAP. Core RNAP at 10 µg/mL was mixed with the sigma factor at various molar ratios and incubated on ice for 15 min. Sigma-dependent transcription activity was measured using the radioactive assay with T4 phage DNA as the template.
Fluorescent assay for RNA polymerase
Assay buffer contained 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 12.5 mM MgCl 2 , 5 mM DTT, 0.5 mM EDTA, and 0.5 mM NaN 3 . Assay mix contained 20 µM (γ-AmNS) UTP, 8 µg/mL T4 phage DNA, 10 µg/mL E. coli core RNAP, 1 µg/mL σ70, and ATP, CTP, and GTP, at 500 µM each, in the assay buffer. Assay was performed in a 50-µL volume in 96-well microplates from Costar. At the end of incubation at 37 °C for 4 h, the assay was stopped by the addition of 10 µL of 150 mM EDTA. Fluorescence was measured in a Victor (Amersham) or Perkin Elmer LS50B fluorescence microplate reader using λex/λem of 360/465 nm.
Fluorescent assay in HTS format
Five microliters of the compound in 1% DMSO were dispensed in Corning 384-well flat-bottom black plates treated to give a nonbinding surface (cat. no. 15801018). This was followed by the addition of 30 µL of 1.66 times concentrated reaction mixture containing 83 mM Tris-HCl (pH 8.0), 83 mM KCl, 8.3 mM DTT, 0.83 mM EDTA, 0.83 mM NaN 3 , 33.2 µM (γ-AmNS) UTP, 13.28 µg/mL T4 DNA, 1.66 µg/mL σ70, and 16.6 µg/mL E. coli core RNAP, using Multidrop (Labsystems, Hoffenberg, Germany). The assay was started by the addition of 15 µL of 3.33 times concentrated start mix containing 1.66 mM each of ATP, GTP, and CTP and 41.66 mM MgCl 2 , using a customized robot called ASSET™, and mixed. At the end of 4 h at 37 °C, the assay was stopped by adding 20 µL of 87.5 mM EDTA using ASSET™ and mixed. Fluorescence was measured at λex/λem of 360/465 nm using Ultra™ (Tecan, Switzerland).
Radioactive assay for RNA polymerase
Assay buffer contained 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 12.5 mM MgCl 2 , 1 mM DTT, and 0.05 mM EDTA. 
RESULTS

Purification of RNAP and sigma factors
Chromatography on DEAE-Sepharose followed by DNA cellulose was sufficient to isolate the core enzyme with >90% purity, as per SDS-PAGE analysis (Fig. 2) . Core enzyme and sigma factors were purified in multiple batches. Yield of E. coli core enzyme was 30 to 40 mg per 100-g wet cell pellet, whereas the yield of M. smegmatis and M. bovis BCG RNAP was 2 to 3 mg and 1 to 2 mg per 50-g wet cell weight, respectively. E. coli core enzyme was purified in gram quantities for HTS. Yield for the sigma factors E. coli σ70 and M. tuberculosis σA was 50 mg per 50-g wet cell pellet. Core enzyme preparations were mostly devoid of any native sigma factors as transcription was observed only after the extraneous addition of sigma factors (Fig. 3) . 
Fluorescent assay
The assay was performed using T4 phage DNA as the template. Incorporation of (γ-AmNS) UTP into RNA was checked in various combinations with the other 3 ribonucleoside triphosphates (rNTPs; Fig. 4 ). There was no increase in fluorescence when (γ-AmNS) UTP was used alone (in the absence of the other 3 rNTPs) or used together with r-ATP but in the absence of sigma factor. Thus, the increase in fluorescence seen when 2 or more rNTPs were used was a direct reflection of the sigmadependent transcription activity of RNAP or RNA synthesis. The signal increased with the number of rNTPs used. Maximum increase in fluorescence at the end of 4 h of incubation at 37 °C was 4-to 5-fold when all rNTPs were used. The time course and protein concentration dependence of the reaction (Fig. 5A,B ) indicated that the assay was linear up to 2.5 h at 37 °C in the presence of 10 µg/mL core RNAP.
HTS
The fluorescent assay was validated for HTS in 384-well plates. Three different sources of plates were tested: regular (Matrix), tissue-culture treated (Costar), and nonbinding surface (NBS; Corning). Data for 2 plates of each type are shown in Table 3 . Intraplate variation was monitored by using standard (Max and Min) and reference wells throughout each experimental run. The Min wells contained 50 mM EDTA, whereas the Max wells contained 1% DMSO. Rifampicin was added in reference wells at 1 µM concentration. The percent coefficient of variation (CV) obtained using NBS plates was within the acceptable limit of 10% and signal-to-background (S/B), signal-to-noise (S/N), and Z´ values of 7 to 7.5, 45 to 70, and 0.7, respectively, were the best among all the plate types tested. EC 50 for rifampicin across plates was between 18 and 21 nM (95% confidence interval [CI]) ( Fig. 6B) , with a maximum of 75% inhibition at 1 µM. The assay mixture was found to be stable (data not shown) at room temperature for 4 h, the expected time required for completing all the additions. Towards the validation of the assay, a subset of 10,000 compounds in duplicate sets of plates was assayed in separate experiments. More than 95% of the compounds showed similar activity in both the tests, thus validating the screen (Fig. 6A) . Following optimization of the assay, throughput of screening up to 100,000 compounds a day was achieved. Compounds showing >50% inhibition at 10 µM were defined as actives. A statistical analysis was also included to capture compounds that did not achieve the 50% activity level but were significantly outside the assay noise. The concentration response was measured in the same assay using 100 µM as the top concentration. A total of 250 compounds out of 670,000 compounds screened at 10 µM had an EC 50 in the range of 5 to 50 µM. These compounds were referred to as "actives."
Confirmation of HTS actives
Hits with an EC 50 value of less than 100 µM for the E. coli enzyme were tested against M. smegmatis RNAP reconstituted with M. tuberculosis σA in a radioactive assay. Eighty percent of the hits had similar activity against both the enzymes. Hit series with an EC 50 less than 50 µM against M. smegmatis RNAP were further tested against M. bovis BCG RNAP before advancing them for the lead generation program.
DISCUSSION
RNA polymerase is a well-validated antimycobacterial target. However, limited attempts have been made to use the enzyme target for HTS. The main reason contributing to this has been the need to purify native enzyme in gram quantities required for an HTS campaign. On the other hand, being a multisubunit enzyme, it has been difficult to obtain robust, reproducible specific activity in preparations of the recombinant enzyme following refolding and reconstitution of core RNAP subunits. We have used the E. coli enzyme for the primary screen and confirmed the activity of putative inhibitors against the M. smegmatis and M. bovis BCG enzymes. The use of the native E. coli enzyme for primary screening was prompted by several reasons. First, most of the crystal structure and enzyme kinetics studies of RNAP have been carried out using native RNAP of Thermus aquaticus or E. coli. Second, purification of native RNAP from a mycobacterial species was extremely difficult as compared to E. coli as the yield was 8 to 10 times lower. Third, there is a high sequence identity at the active site region, and the sequences involved in subunit interactions of RNAP are conserved across various species.
All the enzymes were purified using conventional purification methods described for purifying this native enzyme from whole cells. Even though the expression of wild-type E. coli RNAP with His-tag has been reported earlier, 4 we did not attempt to do the same, as the yield of native RNAP was sufficient to satisfy our need for HTS. However, it will be useful to express M. tuberculosis or M. bovis BCG RNAP with His-tag, as the yield for the wild-type RNAP is very poor. The core enzyme was purified instead of the holoenzyme to ensure only σ70dependent transcription. The reported method of core RNAP purification involves ds-DNA cellulose chromatography followed by gel filtration and phospho-cellulose chromatography. [5] [6] [7] [8] For easy scale-up, we have modified this procedure using only 2 columns, DEAE-Sepharose followed by ds-DNA cellulose. The core RNAP thus purified had few minor contaminating bands compared to that purified through phospho cellulose chromatography (compare lanes 1, 6, and 9 vs. lane 5; Fig. 2) , and the activity was sigma dependent (Fig. 3) .
Apart from the limitations in protein supply, a simple, relatively inexpensive, and 1-step homogeneous assay for RNA polymerase was not available. Radioactive assay for RNAP was not suitable for HTS as it involved filtration and washing steps, whereas the fluorescent assay was a 1-pot assay. The fluorescent assay was designed to detect inhibitors of both transcription initiation as well as elongation. In order to pick up initiation inhibitors, the assay format had to ensure that the transcription was sigma dependent while simultaneously providing all 4 nucleotides permitted elongation and thus the potential to identify elongation-specific inhibitors.
HTS was carried out using a combination of an integrated uHTS system (ASSET™) and offline Multidrop. Initially, all the additions were planned using ASSET™, but it was observed that the T4 phage DNA was sensitive to shearing during recirculation on ASSET™. To overcome this problem, the Multidrop was used for dispensing assay mix containing T4 phage DNA. Similarly, adequate mixing of the well contents on ASSET™ was found to be essential for getting good quality (%CV < 10) data.
The mechanism of rifampicin inhibition is well established. It binds close to the active site of RNAP but does not interfere with the formation of the first phosphodiester bond. 9 It stearically blocks elongation of RNA after the formation of a di/trinucleotide product. T4 phage DNA is rich in adenosine and thymidine nucleotides (64% AT) with 40 strong early promoters. 10 The consensus sequence at the transcription start site has an "A" followed by a pyrimidine residue, which may favor abortive transcription, leading to a significant increase in fluorescence as a result of incorporation of UMP from (γ-AmNS) UTP. This was probably reflected in the maximum inhibition by rifampicin not reaching more than 70% to 80% in this fluorescent assay.
It has been reported that (γ-AmNS) UTP is not used effectively as a substrate by all RNA polymerases (e.g., T7 RNA polymerase). 11 Similarly, in the case of mycobacterial enzymes, the activity window obtained using the fluorescent assay was not sufficient for screening inhibitors (data not shown). It has been reported that (γ-AmNS) UTP is a poor substrate (km of 100 µM as compared to ~40 µM for UTP) for E. coli RNAP. 3 Therefore, it is likely to have a lower affinity for mycobacterial RNAP as compared to E. coli. Moreover, at a higher (γ-AmNS) UTP concentration (>20-30 µM), there was a significant increase in the background fluorescence, resulting in a poor S/N ratio. As a consequence, mycobacterial enzyme activity could not be monitored using this fluorescent assay. Instead, radioactive assay was used as an orthogonal, confirmatory assay. Due to the large difference in the affinity for the unmodified UTP and (γ-AmNS) UTP, a radioactive assay using unmodified UTP could be used to eliminate weak inhibitors, which compete with (γ-AmNS) UTP in the fluorescent assay. We have intentionally biased our screen toward identifying inhibitors, which could be noncompetitive/uncompetitive with the nucleotide substrates so that they might have better selectivity with respect to the eukaryotic enzymes. In addition, the radioactive assay was also useful in eliminating false positives picked up as a result of fluorescence quenching. The fact that 80% of HTS actives were confirmed in the orthogonal radioactive assay using mycobacterial enzymes showed that the percentage of false positives and weak, (γ-AmNS) UTP competitors was indeed low. The 20% of hits that were inactive in the orthogonal assay may represent compounds with higher affinity for E. coli RNAP as compared to mycobacterial RNAP. We are in the process of hit-to-lead optimization of RNA polymerase inhibitors obtained using this assay. This is the first report of an HTS of 670,000 compounds using a homogeneous assay for RNA polymerase that has several advantages over the many different HTS assays reported in the literature, especially in terms of adapting to a high-throughput format. The fluorescent assay using Ribogreen labeling of RNA product may not be suitable for HTS as it involves multiple steps, including ultrafiltration, to remove the contaminating DNA template. 12 The recent report of a fluorescent assay using umbelliferyl ester of ATP may have similar issues as it involves phosphatase treatment before the final readout. 13 In the fluorescent assay that we have reported here, none of the reagents is expensive. On the other hand, reagents used in the homogeneous assays using scintillation proximity and molecular beacons may be more expensive. 14, 15 
APPENDIX
Purification of the core RNA polymerase from E. coli, M. smegmatis, and M. bovis BCG
The purification procedure for all the 3 enzymes was essentially similar. E. coli K12, M. smegmatis mc 2 155, and M. bovis BCG cells were used for the purification of native RNAP. The cell pellet was suspended in a Tris-Cl, glycerol, EDTA, DTT buffer (TGED) buffer containing 25 mM Tris-Cl (pH 8.0), 5% w/v glycerol, 0.1 mM EDTA-Na 2 , 1 mM DTT, 1 mM PMSF, and 1 mM NaN 3 , and cell lysis was carried out in a French pressure cell from Aminco, Inc. (Rochester, NY) at 20,000 psi. Lysate was sonicated to reduce viscosity, and the cell debris was removed by centrifugation at 10,000 g for 15 min. Nucleic acids in the supernatant were precipitated using polyethylene imine (PEI) at a final concentration of 0.8% w/v (10% [w/v] PEI stock solution was neutralized using HCl and dialyzed overnight against water). Nucleic acid precipitate was washed once with TGED buffer, pH 7.6, containing 0.5 M NaCl. RNAP bound to DNA was eluted using TGED buffer, pH 7.6, containing 1M NaCl and subjected to ammonium sulphate precipitation (70% w/v). Ammonium sulphate precipitate was dissolved and dialyzed overnight against TGED buffer, pH 8.0, before loading it onto a DEAE-Sepharose (FF) column. RNAP was eluted with a linear salt gradient of 0 to 600 mM NaCl in TGED buffer, pH 7.6. Activity of RNA polymerase in the eluate fractions was monitored using the fluorescent assay (in the case of E. coli) or the radioactive assay (in the case of the mycobacterial enzymes). Conductivity of the pooled eluate was adjusted so that it matched the conductivity of the TGED buffer, pH 8.0, containing 150 mM NaCl before loading onto a double-stranded calf-thymus DNA cellulose column equilibrated with this buffer. Bound protein was eluted using a linear salt gradient of 150 to 600 mM NaCl. Active fractions were pooled and dialyzed against a storage buffer containing 50 mM Tris-Cl (pH 7.6), 50 mM KCl, 5 mM DTT, 1 mM NaN 3 , 1 mM PMSF, and 50% (v/v) glycerol and stored at -70 °C. The purity of core RNAP was monitored using SDS-PAGE, and protein estimation was performed using the Bradford method. All the purified proteins were tested for nuclease contamination after overnight incubation with the supercoiled plasmid (pBR322) DNA.
Cloning, expression, refolding and purification of E. coli σ σ70 and M. tuberculosis σ σA
RpoD gene (1.8 Kb) of E. coli that encodes for σ70 was amplified from genomic DNA by PCR using the following temperature conditions: 94 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 1.5 min. The cycle was repeated 25 times. The sequence of the primers used was as follows: forward (with EcoR1 site) -5´-AAGAATTCATGGAGCAAAACCCGCAG-3´ and reverse (with Sal1 site) -5´-AAGTCGACTTAATCGTCCAGGAAGCT-3´. The PCR product was cloned into EcoR1-Sal1 sites of pTrc99a to obtain pARC8112 (Fig. 7) . The σA coding gene of M. tuberculosis was cloned in 2 steps. In the first step, the gene fragment encoding N-terminal 111 amino acids was amplified by PCR using the following primers: forward (with Nco1 site) -5´-CGTC-CATGGCAGCGACCAAAGCAAGCACG-3´ and reverse (with BamH1 site) -5´-TCGGGATCCGTTGCGGCTTCGTGCTGG-3´. Temperature conditions were the same as for E. coli rpoD except that extension at 72 °C was for 30 sec. The PCR fragment was cloned into Nco1-BamH1 sites of pET8cKm (pET8c with a kanamycin resistance marker) to obtain pARC8170. In the second step, a 1.4-Kb BamH1-EcoRV fragment encoding the remaining C-terminal part of the σA was released from a construct in pBR322 bearing full-length σA, which had been obtained from a library of M. tuberculosis genomic DNA. The 1.4-Kb gene fragment was cloned into BamH1-EcoRV sites of pARC8170 to obtain pARC8171 (Fig. 8) , thus placing σA of M. tuberculosis behind the T7 promoter.
Recombinant E. coli σ70 and M. tuberculosis σA were overproduced in E. coli BL21 (DE3), freshly transformed with the respective plasmids. Cells were grown in Luria broth at 37 °C until OD 600 reached 0.6. Expression of σA was induced by adding 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG). At the end of 3 h, cells were harvested, washed, and resuspended in phosphate-buffered saline (PBS), pH 7.5, to get a 20% (w/v) suspension. Cell suspension was passed through a French pressure cell at a pressure of 1500 psi, and inclusion bodies were pelleted after centrifugation at 10,000 g for 20 min. This pellet was resuspended in PBS (pH 7.5) and loaded on a 2-step sucrose gradient (prepared in the same buffer), 15% (8 mL) and 60% (2 mL), and centrifuged at 100,000 g for 1 h. Inclusion bodies at the bottom of the gradient were washed with PBS containing 0.1% Triton-X-100 and solubilized in the denaturation buffer containing 50 mM Tris-Cl (pH 8.0), 6 M guanidine HCl, 10% glycerol, 10 mM MgCl 2 , 10 µM ZnCl 2 , 1 mM EDTA, 10 mM DTT, and 1 mM PMSF. After solubilization at room temperature for 30 min, protein concentration was adjusted to 0.3 mg/mL using the denaturation buffer, and insoluble debris was removed by centrifugation at 100,000 g for 30 min. Denatured σ70/σA was refolded by dialyzing against the renaturation buffer containing 50 mM Tris-Cl (pH 8.0), 200 mM KCl, 20% glycerol, 10 mM MgCl 2 , 10 µM ZnCl 2 , 1 mM EDTA, 1 mM DTT, and 1 mM PMSF. Refolded σ70/σA was clarified by centrifugation at 100,000 g for 30 min and dialyzed against the buffer containing 50 mM Tris-Cl (pH 8.0), 5% glycerol, 0.1 mM DTT, and 0.1 mM EDTA and loaded on a DEAE-Sepharose column equilibrated with the same buffer. Bound protein was eluted with a salt gradient of 0 to 500 mM NaCl in 5-column volumes at a flow rate of 1 mL/min. Individual fractions were checked for nonspecific nuclease contamination after incubation with supercoiled plasmid DNA and MgCl 2 . Nuclease-free fractions were pooled, concentrated, dialyzed against the renaturation buffer, and stored at -20 °C.
